A technical deep dive for pharma IP teams, R&D leads, and institutional investors on the world’s most consequential pharmaceutical patent provision.
Key Takeaways: The Short Version for Busy Analysts
India’s Section 3(d) is the only pharmaceutical patent provision in the world that demands a specific type of functional proof, therapeutic efficacy, before a new form of a known drug can be considered an invention at all. It is not India’s version of the obviousness inquiry; it is an additional, upstream filter that operates before novelty and inventive step even enter the conversation.
The Supreme Court’s 2013 ruling in Novartis AG v. Union of India defined ‘efficacy’ in pharmaceutical cases as therapeutic efficacy exclusively. Improved physicochemical properties, including a 30% increase in oral bioavailability demonstrated by Novartis for imatinib mesylate’s beta crystalline form, did not qualify. The Court placed an explicit evidentiary burden on the applicant to demonstrate that a pharmacokinetic improvement translates into a superior clinical outcome.
Since that ruling, three further developments have reshaped the provision’s practical scope: its extension to biochemicals via Novozymes A/S v. Assistant Controller (Madras HC, 2023); the Calcutta High Court’s 2025 ruling in Oramed Ltd. v. Controller General enforcing a clean procedural boundary between Section 3(d) and 3(e); and a series of Delhi High Court orders mandating that IPO examiners identify the ‘known substance’ and construct a reasoned comparator before issuing a 3(d) objection.
Empirical analysis of Indian First Examination Reports shows the share of pharmaceutical applications receiving a Section 3(d) objection has risen from under 40% in the early 2000s to above 80% in recent filing cohorts. The provision is now being applied to new chemical entities, not just secondary patents, which suggests the IPO is using it as a heightened utility requirement irrespective of its statutory text.
For institutional investors, Section 3(d) creates a measurable, modelable risk discount on the Indian market exclusivity component of any small-molecule drug’s NPV. Secondary patents covering polymorphs, salts, esters, and sustained-release formulations, which typically represent 40-60% of a drug’s effective patent life in the US, carry near-zero IP value in India unless accompanied by published comparative clinical data.
1. What Section 3(d) Actually Says — and Why the Text Matters
The Statutory Language
Section 3(d) of the Indian Patents Act, 1970 (as amended in 2005) holds that the following are not inventions within the meaning of the Act:
‘the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant.’
The Explanation that follows is where the operational weight sits: ‘For the purposes of this clause, salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy.’
The provision has three distinct prohibitory limbs. The first bars patents on new physical forms of known substances absent enhanced efficacy. The second bars patents on new properties or new uses discovered for known substances. The third bars the use of a known process, machine, or apparatus as an invention unless it produces a new product or incorporates at least one new reactant.
Why the Explanation Is the Real Enforcement Mechanism
The statutory list in the Explanation, covering salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, and combinations, is not illustrative. It is a legal presumption. When a patent examiner sees a claim covering a new crystalline polymorph or a pharmaceutically acceptable salt of a known API, the Explanation instructs the examiner to treat that compound as the same substance as the known drug. The burden then shifts entirely to the applicant to rebut that presumption with evidence of significant property differences with regard to efficacy.
That burden reversal is what distinguishes Section 3(d) from every other patent system on earth. In the US or Europe, an examiner who wants to reject a polymorph patent for lack of inventive step must build an obviousness case using prior art. In India, the examiner simply invokes the Explanation, labels the compound a derivative of a known substance, and hands the applicant the problem of disproving that characterization.
Defining ‘Known Substance’: The Threshold Question
Before the efficacy comparison even begins, a threshold question must be answered: what is the ‘known substance’ against which the new form is being compared? This question, which sounds simple, generated a substantial body of contradictory IPO practice until the Delhi High Court imposed procedural discipline in DS Biopharma Limited v. The Controller of Patents and Designs. The court held that an examiner cannot issue a valid 3(d) objection without specifically identifying the prior art compound that constitutes the baseline. A vague reference to ‘the known compound in this therapeutic class’ is insufficient. The examiner must name it, cite the prior art document that discloses it, and establish a structural or functional relationship between that compound and the claimed invention.
For applicants, this procedural holding creates a viable avenue for challenging poorly constructed IPO objections at the first examination stage rather than in post-grant opposition or litigation.
2. The TRIPS Transition: How India Built a Legal Moat Around Generics
The 1970 Patents Act and India’s Process-Only Regime
India’s 1970 Patents Act excluded product patents for pharmaceuticals, food, and chemicals. Only process patents were available, and those were limited to seven years from the date of sealing or five years from the date of patent, whichever was shorter. The deliberate policy rationale was that domestic manufacturers should be free to reverse-engineer any molecule and find alternative synthesis routes, driving manufacturing costs down and ensuring wide drug availability.
The practical result was the construction of what is now the world’s largest generic pharmaceutical industry by volume. Companies including Cipla, Sun Pharma, Dr. Reddy’s Laboratories, Aurobindo, Lupin, and Torrent built their entire competitive structures on the ability to copy patented molecules, improve their synthesis economics, and sell at prices often 80-95% below the originator’s Western market price. Cipla’s 2001 offer to supply triple antiretroviral therapy for HIV/AIDS to African nations at $350 per patient per year, when branded equivalents cost $12,000-15,000 in the US, came directly from this legal and manufacturing ecosystem.
TRIPS Compliance and the 2005 Amendment
India joined the WTO in 1995 and entered the TRIPS agreement with a transitional period for pharmaceutical product patent introduction. The January 1, 2005 deadline for TRIPS Article 27.1 compliance required full product patent coverage across all fields of technology, including pharmaceuticals, with a 20-year term.
The Patents (Amendment) Act, 2005 introduced the required product patent regime. It also introduced the ‘mailbox’ provision for applications filed between 1995 and 2005, and it gave India’s public health advocates, domestic generics industry, and left-leaning political parties leverage to negotiate aggressive safeguards into the implementing legislation. Section 3(d) was the most visible result of that negotiation, but other safeguards were embedded alongside it: compulsory licensing provisions in Sections 84-92, which the government exercised in 2012 for Bayer’s sorafenib (Nexavar); pre-grant opposition rights under Section 25(1); and post-grant opposition rights under Section 25(2).
The Legislative Origins of the ‘Enhanced Efficacy’ Language
The drafting history of the final Section 3(d) text is genuinely opaque. Analyses of parliamentary records by Shamnad Basheer, then at Oxford, and later corroborated by SpicyIP research, confirmed that the final potent version of the clause, including the Explanation and the ‘enhanced efficacy’ language, materialized almost without legislative record one day before the bill was tabled in Parliament. Authorship was attributed to a retired Supreme Court judge with documented pro-public health, skeptical-of-IP views. There is no committee report, no drafting memo, and no explanatory note that defines what ‘efficacy’ means, what ‘significantly’ means as a threshold, or how the comparison between the new form and the known substance should be constructed.
This legislative vacuum was not an oversight. It was a structural feature. By leaving key terms undefined, the drafter ensured that Section 3(d) would require judicial construction to become operational, placing the interpretive work with courts rather than Parliament, and thereby insulating the provision from direct political pressure from trading partners. The US Trade Representative’s annual Special 301 Report has placed India on its Priority Watch List for years, citing Section 3(d) among its concerns, but judicial interpretations of domestic patent law are far harder to challenge in trade negotiations than explicit statutory exclusions.
Key Takeaways: The TRIPS Transition
Section 3(d) was not a compliance failure. It was a deliberate exercise of TRIPS flexibility, specifically the absence of a TRIPS-mandated definition of ‘invention,’ to impose a higher patentability standard on incremental pharmaceutical modifications. The provision’s deliberately sparse drafting made it resilient to bilateral trade pressure while creating enormous scope for judicial expansion. India’s generic industry, valued at approximately $50 billion in domestic and export revenue as of 2024, is the direct economic beneficiary of that architecture.
3. The Novartis/Gleevec Decision: Therapeutic Efficacy as the Standard
The Asset at Stake: Gleevec’s IP Architecture and Valuation
To understand Novartis AG v. Union of India, the analyst must first understand what Novartis was actually trying to protect. Imatinib, the active pharmaceutical ingredient in Gleevec (marketed as Glivec in India and Europe), is a BCR-ABL tyrosine kinase inhibitor approved by the FDA in May 2001 for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. The compound itself was covered by a primary composition-of-matter patent filed in the early 1990s (US 5,521,184, granted 1996), which Novartis held outside India but which predated the Indian product patent regime.
When India opened its mailbox applications in 2005, Novartis’s application was for the beta crystalline form of imatinib mesylate, a specific polymorphic variant of the salt form of the compound. This was a secondary patent, sometimes called a follow-on patent or improvement patent, built on top of a primary NCE that was already unpatentable in India due to the 1970 Act’s exclusions. The specific claims covered crystal structure, X-ray diffraction pattern, and physical properties including thermodynamic stability, low hygroscopicity, and improved flow characteristics.
From an IP valuation standpoint, Novartis was seeking to use the patent on the beta crystalline form as a de facto product patent over imatinib mesylate itself, given that the API in every tablet of Gleevec is this specific polymorph. Priced at approximately $70,000 per patient per year in the US at the time, and with roughly 20,000 CML patients in India, the Indian market exclusivity value was substantial, though it paled against Gleevec’s global peak revenues of $4.7 billion annually. The more consequential concern for Novartis was precedent: losing this patent in India meant losing the template for all future secondary patent strategy across its global portfolio in the Indian market.
The Imatinib Mesylate Chain: Structure-Activity and the Polymorphism Question
The technical dispute in the case required courts to understand a pharmaceutical chemistry concept that most lawyers and judges encounter rarely. Imatinib free base converts to imatinib mesylate through a salt formation reaction with methanesulfonic acid. The mesylate salt exists in multiple polymorphic forms, designated alpha and beta. Polymorphs are distinct crystal structures of the same chemical compound, each with different unit cell parameters, X-ray powder diffraction (XRPD) patterns, melting points, solubility, and physical handling properties.
Novartis’s beta crystalline form patent asserted that the beta polymorph was advantageous for manufacturing because of its superior stability and flow. The company also presented data showing the beta polymorph had approximately 30% higher bioavailability than the alpha form, and that imatinib mesylate as a whole had higher bioavailability than the imatinib free base.
The applicant’s argument was structurally sound by US or European standards. In the US, demonstrating unexpected results, specifically a 30% bioavailability improvement over the closest prior art, is a recognized secondary consideration for non-obviousness. At the EPO, improved bioavailability constitutes a valid technical effect sufficient to identify an objective technical problem and establish inventive step under the problem-solution approach. Neither jurisdiction asks whether the bioavailability improvement translates into better clinical outcomes. The question stops at the technical effect.
The Supreme Court’s Interpretive Framework
The Supreme Court, in its judgment delivered April 1, 2013, authored by Justice Aftab Alam, conducted a thorough review of Section 3(d)’s legislative history and concluded that the provision’s entire purpose was to prevent evergreening of pharmaceutical patents by setting a higher, substantively different patentability standard for this specific class of incremental inventions.
The Court’s interpretation of ‘efficacy’ was unambiguous: for a pharmaceutical substance, ‘efficacy’ means ‘therapeutic efficacy.’ The Court reasoned that a drug’s function is therapeutic, and therefore any claimed enhancement in efficacy must relate to that function. Physical properties such as flow characteristics, thermodynamic stability, and hygroscopicity affect manufacturing but not treatment. They have no bearing on whether the drug cures or treats the disease more effectively.
On bioavailability, the Court drew a careful distinction. Bioavailability is a pharmacokinetic parameter. It measures the fraction of an administered dose that reaches systemic circulation in an active form. Higher bioavailability is often, but not always, associated with better therapeutic outcomes. The Court held that the causal link between bioavailability and therapeutic efficacy is not self-proving. An applicant who claims enhanced efficacy on the basis of increased bioavailability must provide clinical or pharmacodynamic evidence that the higher systemic exposure actually produces a better therapeutic response: faster disease control, higher response rate, longer duration of remission, reduced toxicity, or a demonstrably improved patient outcome. Novartis had not provided such data, and the Court found the 30% bioavailability improvement insufficient on its own to establish enhanced therapeutic efficacy.
The ruling also addressed the ‘known substance’ baseline. The Court held that the comparison for Section 3(d) purposes was between the claimed beta crystalline form and imatinib mesylate as the known substance, not between the beta form and the imatinib free base. Since Novartis had shown the beta form to have comparable therapeutic efficacy to the mesylate (the approved drug), it had failed to show enhancement over the correct baseline. There was a structural irony in this: Novartis’s own clinical success with Gleevec proved that the approved mesylate formulation was already highly effective, making it harder, not easier, to show that the beta polymorph was therapeutically superior to it.
Why the Decision Created a Practical Catch-22 for Secondary Patents
The Court’s high evidentiary bar generates a structural problem for innovator drug development that deserves explicit analysis. Pharmaceutical companies file secondary patents covering polymorphs, salts, and formulations early in development, often before or during Phase II trials, specifically to extend effective market exclusivity before large clinical datasets exist. The patents are meant to protect the optimized dosage form that will be commercialized, and they typically claim advantages in stability, manufacturing efficiency, or preliminary pharmacokinetic data.
Under the Novartis standard, an Indian patent application for this type of secondary patent must include, or later submit, evidence from comparative clinical or pharmacodynamic studies demonstrating superior therapeutic performance relative to the baseline compound. That evidence typically does not exist at the time of filing because the clinical trials have not been conducted. By the time Phase III data that could support a therapeutic efficacy argument exists, the patent application’s priority date has long been established, but the prosecution burden remains: the applicant must supplement the record with post-filing evidence.
The post-filing evidence pathway exists under Sections 57, 59, and 79 of the Patents Act, and the Calcutta High Court confirmed its availability in Oyster Point Pharma Inc. v. Controller of Patents and Designs (2023). But the strategic clock is unforgiving. Generic manufacturers file pre-grant oppositions as soon as applications are published (typically 18 months after filing), and a well-resourced generic challenger can request expedited examination. The result is a prosecution timeline where the innovator must generate, obtain, and submit clinical comparison data while simultaneously defending against opposition proceedings, all before a grant decision.
Key Takeaways: The Novartis Framework
‘Therapeutic efficacy’ is the only lens through which Section 3(d) evaluates a pharmaceutical compound’s improvement. Physicochemical advantages do not qualify. Bioavailability improvements do not qualify unless linked to clinical outcomes through empirical data. The known substance comparator is the directly preceding compound in the chemical family, not the original NCE. Post-filing evidence of therapeutic efficacy is admissible and often necessary, but creates a compressed prosecution window vulnerable to opposition.
Investment Strategy: Gleevec as a Valuation Case Study
Analysts pricing Novartis’s India-market Gleevec franchise at any point between 2006 and 2013 should have discounted the secondary patent’s contribution to Indian market exclusivity to near zero. The correct valuation model for any secondary pharmaceutical patent in India requires the following adjustment: if the patent covers a salt, polymorph, ester, or formulation of an approved API, its India-market exclusivity value is conditional on the existence of published comparative clinical data showing therapeutic superiority. Absent that data, assign the patent a minimal India-market exclusivity value, because Section 3(d) exposure is high and pre-grant opposition by domestic generics is near-certain for any commercially significant asset.
Novartis’s global Gleevec revenue was largely insulated from the Indian ruling, because patent protection in the US, EU, Japan, and other major markets was unaffected. The practical consequence was that Novartis lost Indian market exclusivity on a drug generating $4.7 billion annually in global peak sales, but India was never a material revenue contributor for Gleevec at innovator pricing. The ruling’s lasting financial impact on Novartis was reputational and strategic: every secondary patent in its India portfolio subsequently faced an elevated challenge risk, and global patent strategy for all future development-stage assets had to be rebuilt to account for the Indian therapeutic efficacy requirement.
4. Post-Novartis Judicial Evolution: Expansion, Clarification, and Procedural Discipline
Novozymes A/S v. Assistant Controller of Patents (Madras HC, 2023): Section 3(d) Beyond Pharma
The Novartis ruling addressed therapeutic efficacy in the context of a small-molecule CML drug. A decade later, the Madras High Court addressed a structurally different question: does Section 3(d) reach beyond pharmaceutical compounds to biochemicals and industrial enzymes?
The case involved Novozymes A/S, the Danish enzyme manufacturer with global sales exceeding $2 billion annually from enzyme solutions used in animal nutrition, food processing, biofuels, and household detergents. The company had filed a patent application for a thermostable variant of phytase, an enzyme that cleaves phytic acid in animal feed, releasing bound phosphorus and improving digestive efficiency in pigs and poultry. The IPO rejected the application under Section 3(d), treating the engineered phytase variant as a new form of a known substance (wild-type phytase) without demonstrated enhanced efficacy.
Novozymes challenged the rejection on two grounds: that Section 3(d) should not apply to non-pharmaceutical biochemicals at all, and that in any event the thermostability improvement constituted enhanced efficacy for the enzyme’s industrial function.
The Madras High Court ruled against the first ground and for the second. On the scope question, the court noted that the statutory text says ‘known substance,’ not ‘known pharmaceutical substance.’ The Explanation’s list of derivatives, including metabolites, salts, and polymorphs, has clear analogues in biochemistry. A mutant enzyme is functionally analogous to a polymorph: same compound identity at the molecular level, different physical properties. Section 3(d) applies.
On the efficacy question, the court adopted a context-specific approach that diverges instructively from Novartis. The court held that ‘efficacy’ should be evaluated by reference to the intended function of the substance in its field of application. For a pharmaceutical, the function is therapeutic, and so efficacy is therapeutic. For an industrial enzyme designed to withstand the pelleting temperatures (typically 80-90 degrees Celsius) used in feed manufacturing, efficacy is its ability to survive that thermal processing and remain active in the animal’s digestive system. Improved thermostability, demonstrated by the variant’s retention of 85% activity at 90 degrees versus the wild-type’s 30% retention, was directly relevant to the enzyme’s performance in its intended use case. The court accepted this as evidence of enhanced efficacy and remanded the application for reconsideration.
The IP valuation implication for Novozymes and similarly structured companies is significant. Novozymes’s patent portfolio on enzyme variants is a core asset. Its 2022 annual report attributed substantial competitive moat value to enzyme IP. In India, the Novartis risk was previously treated as a pharma-only concern. After Novozymes, the IP departments of any enzyme manufacturer, crop protection company, or industrial biology firm filing in India must treat Section 3(d) as an active examination risk and build function-specific efficacy data into their prosecution strategy.
Oramed Ltd. v. Controller General of Patents (Calcutta HC, July 2025): Enforcing the 3(d)/3(e) Boundary
Oramed Pharmaceuticals develops oral insulin delivery technology. Its patent application in India covered an oral peptide drug formulation, and the Controller rejected it partly under Section 3(e), which bars patents for substances obtained by ‘mere admixture’ of known components unless the admixture produces a synergistic effect. The Controller’s reasoning mixed Section 3(d) and 3(e) criteria, demanding data on therapeutic efficacy and bioavailability improvement as conditions for the 3(e) synergism test.
The Calcutta High Court overturned the rejection. The court’s analysis is useful precisely because it is mechanically precise. Section 3(d) asks whether a new form of a known substance shows enhanced efficacy over that substance. Section 3(e) asks whether a combination of known components produces a result that the components could not achieve individually, specifically a synergistic effect. These are different questions, tested against different benchmarks, and requiring different types of evidence. The Controller cannot import the therapeutic efficacy data requirement from 3(d) into a 3(e) analysis, nor demand bioavailability comparisons for what is fundamentally a synergism question. Doing so conflates distinct legal tests and renders the examiner’s objection legally defective.
For practitioners, the ruling provides a direct procedural counter to blended IPO objections. When an FER cites both 3(d) and 3(e) and applies identical data demands to both, the examiner has likely conflated the standards. The appropriate response in prosecution, or in a hearing before the Controller, is to force the IPO to specify which objection applies to which claim feature, and to hold the examiner to the correct legal test for each.
DS Biopharma and Nippon Steel: Procedural Fairness as an Independent Ground for Remand
The Delhi High Court has been the primary enforcement mechanism for procedural quality in Section 3(d) examinations. In DS Biopharma Limited v. Controller of Patents and Designs and Nippon Steel Corporation v. Controller General of Patents, the court articulated a three-part test that an examiner must satisfy to issue a legally valid 3(d) objection.
The examiner must identify the specific prior art compound constituting the ‘known substance.’ The examiner must explain, with reference to the structural or functional relationship between the claimed compound and the identified prior art, why the claimed compound is a derivative or new form of that substance. The examiner must frame the objection in sufficiently specific terms to allow the applicant to conduct a meaningful, objective comparison of therapeutic efficacy between the two compounds.
Failure on any of the three elements is grounds for remand. The Delhi HC has applied this standard strictly, overturning multiple IPO rejections on procedural grounds without reaching the substantive efficacy merits. For innovator patent holders, these decisions create a viable first-line defense against poorly reasoned Section 3(d) rejections: challenge the procedural adequacy of the objection before engaging on the substantive efficacy data.
This judicial oversight has imposed a documentation discipline on IPO examiners that was previously absent. Examination quality is improving as a result, though pendency, currently averaging over four years for pharmaceutical applications, remains a significant commercial problem.
Key Takeaways: Post-Novartis Developments
Section 3(d) now reaches biochemicals, with efficacy defined by the substance’s intended function rather than by therapeutic outcome alone. Sections 3(d) and 3(e) are legally distinct and require distinct types of evidence; blended objections relying on both standards simultaneously are vulnerable to procedural challenge. The IPO must identify the known substance and construct a reasoned comparator to issue a valid 3(d) rejection, creating a three-part procedural test that practitioners can deploy against inadequately reasoned FER objections.
5. The Indian Patent Office in Practice: Empirical Trends in Section 3(d) Examination
Rising Objection Rates and Their Significance
Academic analysis of First Examination Reports published in PLOS ONE (Sampat and Shadlen, 2018) provides the most systematic empirical picture of Section 3(d) in practice. Examining a cohort of pharmaceutical patent applications filed between 1995 and 2010, the study found that the probability of receiving a 3(d) objection increased sharply after the 2005 amendment and continued rising through the observation period. Applications filed in the 2005-2010 cohort faced a 3(d) objection in over 80% of cases, up from less than 40% in the pre-amendment period.
Grant rates for applications receiving a 3(d) objection are measurably lower than for applications receiving only novelty or inventive step objections. The pendency gap is substantial: applications facing Section 3(d) objections take several hundred additional days on average to reach a final decision compared to applications that receive only traditional patentability rejections.
The Redundancy Pattern: Belt-and-Suspenders Examination
More than 94% of Section 3(d) objections are raised in combination with a lack of inventive step or novelty objection rather than as the sole ground. This co-citation pattern has generated academic debate over whether Section 3(d) is doing independent work or is simply a rhetorical add-on to rejections that would succeed on traditional grounds.
The evidence suggests it does independent work, though the mechanism is indirect. Even when an application overcomes an inventive step objection through prosecution, the 3(d) objection independently requires a separate showing of enhanced therapeutic efficacy. Satisfying inventive step through unexpected results data (a valid argument before the IPO) does not automatically satisfy the therapeutic efficacy standard, because the two tests measure different things. An applicant who demonstrates that their compound’s improved stability was unexpected in light of the prior art has cleared the inventive step bar but has not shown that the stability improvement produces better clinical outcomes, which is what 3(d) demands.
The practical result is that 3(d) functions as a second substantive filter even when it appears co-joined with other grounds, forcing applicants to address both the technical unexpectedness of their invention and its clinical consequences.
The New Chemical Entity Paradox
The Sampat and Shadlen data reveals that Section 3(d) objections are raised against applications claiming new chemical entities at a non-trivial rate. This is analytically puzzling. Section 3(d) targets new forms of known substances. A genuine NCE is, by definition, not a known substance, so the Explanation’s presumption should not trigger.
The IPO’s apparent logic is one of preemptive burden-shifting. By raising a 3(d) objection even against an NCE claim, the examiner forces the applicant to affirmatively demonstrate therapeutic value at the prosecution stage. This is a de facto heightened utility requirement, similar in function to the FDA’s requirement for evidence of pharmacological activity before an IND application. It is legally questionable because the statutory text does not support applying the provision to compounds that are not derivatives of known substances. But it is practically effective because applicants who have clinical data respond by submitting it, and applicants who lack data must either generate it or abandon the India prosecution.
The patent grant surge reported by WIPO for India in 2023, with Indian patent grants rising sharply as a share of global filings, should be read against this backdrop. Aggregate grant numbers are rising, but the average prosecution cost and timeline for pharmaceutical applications in India is significantly higher than in comparable OECD jurisdictions. The number conceals a composition effect: India is granting more patents while also maintaining more intensive examination of pharmaceutical applications specifically.
Prosecution Timeline Benchmarks
Pharmaceutical patent applications in India face average pendency of four to five years from filing to final decision. Applications receiving Section 3(d) objections extend this timeline by an estimated 20-30% based on prosecution history analysis. Pre-grant oppositions, available to any person under Section 25(1) upon application publication, can add further delays, and generic manufacturers have built systematic pre-grant opposition programs specifically targeting secondary pharmaceutical patents at application publication.
For lifecycle management purposes, an innovator company filing a secondary patent in India should budget for a five-to-seven-year prosecution window and should expect a pre-grant opposition within 18 months of publication. The window between grant and any generic launch is correspondingly compressed.
6. IP Valuation Under Section 3(d): How the Provision Reprices Drug Assets
The Standard NPV Model and Its Section 3(d) Adjustment
A standard pharmaceutical NPV model values each patent separately as a component of market exclusivity. For a typical small-molecule drug reaching peak sales, the primary composition-of-matter patent covers the core compound and expires 20 years from filing, often giving 12-15 years of effective market exclusivity post-approval when accounting for development time. Secondary patents covering polymorphs, new salt forms, specific formulations, new routes of administration, and new indications can extend effective exclusivity by 2-8 additional years in markets where those patents are upheld.
In the US, the secondary patent contribution to NPV is substantial. The Paragraph IV challenge mechanism under the Hatch-Waxman Act creates well-defined litigation risk for those patents, but many secondary patents survive challenge and deliver real exclusivity extension. A sustained-release formulation patent, for example, can add three to five years of exclusivity if the generic challenger cannot demonstrate that the formulation was obvious or that FDA approval of a generic version would not infringe.
In India, the Section 3(d) discount on secondary patent NPV is severe. The correct adjustment in a valuation model is to treat the India-market exclusivity value of any secondary patent as conditional probability weighted. The condition: does published comparative clinical data exist demonstrating enhanced therapeutic efficacy of the specific form or formulation over the baseline compound? If the answer is no, and it frequently is for polymorphs and standard salts, the conditional probability of that patent surviving a pre-grant or post-grant opposition challenge is materially below 50%. The discount factor on that patent’s India-market exclusivity contribution should reflect that probability.
For a drug generating $100 million annually in India at innovator pricing under a secondary patent, and where the secondary patent contributes 3 additional years of exclusivity, the Section 3(d)-adjusted NPV loss compared to the base case (where the patent holds) is the present value of approximately $300 million in Indian revenue at a high discount probability. In practice, India’s innovator market share for affected drugs tends to be much smaller because generics launch pre-emptively once the primary patent expires, relying on the near-certain eventual invalidation or refusal of the secondary patent.
The Gleevec Pricing Spread as a Reference Point
The pricing differential in the Gleevec case, approximately $70,000 per patient per year in the US versus $2,500 in India for generic imatinib, illustrates the full magnitude of the India market exclusivity value at stake. But it also illustrates why the India NPV contribution of the secondary patent was modest in absolute terms even before the Supreme Court decision. India’s purchasing power parity environment meant that Novartis’s realistic India revenue at innovator pricing was constrained regardless of patent status. The real economic stakes for Novartis were in other markets with strong secondary patent protection and high drug prices. India’s significance was precedential, not purely financial.
For drugs with larger India revenue profiles, the arithmetic changes. A primary care diabetes or cardiovascular drug with broad Indian prescribing and a secondary formulation patent can represent meaningful India NPV if the secondary patent holds. Analysts covering companies with large India exposure, including Sun Pharma’s branded generic segments or Pfizer India, should model the 3(d) vulnerability of every secondary patent in the portfolio.
IP Valuation Across the Section 3(d) Exposure Spectrum
The following framework ranks secondary patent types by their relative Section 3(d) vulnerability, from highest to lowest risk:
Polymorphs of approved API salts carry the highest vulnerability. The Explanation directly lists polymorphs as presumptive derivatives, and proving therapeutic superiority for a crystal structure change is exceptionally difficult because the therapeutic activity of the drug is identical regardless of crystalline form. Unless the polymorph enables a meaningfully different clinical dosing regimen or a documented reduction in adverse effects at the same dose, a 3(d) objection is nearly untenable to defeat.
New pharmaceutical salts of approved APIs carry high vulnerability. The Explanation lists salts explicitly. The applicant must show that the new salt produces superior therapeutic outcomes, not merely better solubility, hygroscopicity, or manufacturability. The cases where this is achievable are narrow, primarily where the new salt form enables a route of administration change (oral versus injectable) that carries direct clinical benefits.
New formulations, including sustained-release, modified-release, and fixed-dose combinations, carry moderate vulnerability. The analysis depends heavily on whether the formulation change produces documented clinical advantages. Once-daily dosing from a twice-daily regimen has arguable therapeutic benefits via improved compliance, though IPO examiners and courts have not uniformly accepted compliance-based arguments as sufficient therapeutic efficacy evidence. A new formulation that enables a 50% dose reduction with equivalent efficacy, or that demonstrably reduces peak-concentration-related side effects, presents a stronger case.
New routes of administration carry moderate-to-low vulnerability, particularly where the route change addresses a clinical limitation of the existing administration method. An intranasal or inhaled formulation of a drug previously requiring injection addresses patient burden directly and can demonstrate therapeutic benefit in terms of compliance outcomes, onset time, or pediatric appropriateness.
New indications for known compounds carry high vulnerability under the second limb of Section 3(d), which bars ‘the mere discovery of any new property or new use for a known substance.’ This limb effectively prevents Swiss-form or use-claim patents for new therapeutic applications of known drugs, a strategy widely used elsewhere to extend effective exclusivity on approved compounds.
7. Evergreening Tactics and Their Section 3(d) Exposure: A Technology Roadmap
What Evergreening Means in Practice
Evergreening is the generic term for the commercial strategy of obtaining a new patent, or a series of new patents, on modifications of an approved drug to extend effective market exclusivity beyond the primary composition-of-matter patent’s expiry. The strategy is legal in most jurisdictions where incremental improvements are patentable, and it is commercially rational because the R&D cost of developing a polymorph, a new salt form, or a sustained-release formulation is a fraction of the cost of developing a new molecular entity.
The I-MAK (Initiative for Medicines, Access and Knowledge) 2018 report on evergreening documented that top-selling US drugs had received an average of 125 patent applications each, extending potential exclusivity for an average of 38 years beyond the primary patent’s expiry date. AbbVie’s adalimumab (Humira) is the most-cited example, with over 250 patent applications generating a patent thicket that delayed biosimilar entry in the US until 2023 despite FDA approval of biosimilars years earlier.
In India, Section 3(d) systematically disrupts the evergreening playbook at the secondary patent stage. Each major evergreening tactic must be evaluated against its specific 3(d) exposure.
Polymorph Patents
A polymorph patent covers a specific crystal form of an approved compound or its salt. The pharmaceutical rationale for polymorph optimization is real: different crystal forms have different physical stability, solubility, melting points, and processing characteristics, and selecting the optimal polymorph is a legitimate part of dosage form development. In the US and Europe, demonstrating that the polymorph was non-obvious (due to, for example, unexpectedly high stability) is typically sufficient.
India’s Section 3(d) Explanation directly designates polymorphs as derivatives of known substances. To secure a polymorph patent in India, the applicant must show enhanced therapeutic efficacy over the approved compound. The only viable routes to meeting this standard are: demonstrating that the polymorph form enables a different and clinically superior dosing regimen, showing that the polymorph’s physical properties (such as extended dissolution kinetics) produce a pharmacokinetic profile with measurably better clinical outcomes compared to the existing form, or proving that the polymorph significantly reduces a safety-relevant side effect. All three routes require clinical or robust pharmacodynamic evidence. Most polymorph filings lack this evidence at prosecution stage. Expected grant rate for polymorph secondary patents in India: low, estimated below 20% when contested by a pre-grant opponent with access to published therapeutic comparability data.
New Salt Forms
Salt selection is a critical step in pharmaceutical development. The correct salt form can dramatically improve aqueous solubility, bioavailability, stability, and crystallinity. The pharmaceutical industry files patents on new salt forms routinely. AstraZeneca’s esomeprazole (Nexium) is the canonical example, where a new single-enantiomer version and its magnesium salt form extended exclusivity after omeprazole (Prilosec) went generic.
In India, esomeprazole magnesium faced pre-grant opposition, and the IPO’s examination of Nexium-related secondary patents exemplifies the Section 3(d) dynamic. Without data showing that the magnesium salt of esomeprazole produces superior acid suppression or healing rates compared to omeprazole or racemic esomeprazole, a 3(d) objection is nearly certain. AstraZeneca’s clinical data on esomeprazole’s efficacy compared to omeprazole was contested in the medical literature, with multiple meta-analyses showing marginal clinical differences at best. That evidentiary ambiguity, sufficient to support marketing claims in many Western markets, is unlikely to satisfy India’s enhanced therapeutic efficacy standard.
Fixed-Dose Combinations
Fixed-dose combinations (FDCs) are pharmaceutical products containing two or more active ingredients in a single dosage form. They are widely used in infectious diseases, cardiovascular disease, diabetes, and HIV/AIDS treatment. From a patent perspective, an FDC combining two known drugs can be patented in most jurisdictions if the combination is non-obvious or produces a synergistic effect.
Under Indian law, FDCs face examination under Section 3(e) (mere admixture) and potentially 3(d) for each component if any component is a new form of a known substance. The 3(e) synergism standard requires evidence that the combination produces an effect greater than the sum of its parts, demonstrated in comparative clinical or pharmacological studies. Given India’s high burden of infectious disease and the central role of FDCs in national treatment guidelines (particularly for tuberculosis, HIV, and hypertension), the IPO’s treatment of FDC patents is commercially consequential for both originator and domestic manufacturers seeking to patent proprietary combination products.
Prodrugs and Metabolites
A prodrug is a pharmacologically inactive compound that converts to an active drug through metabolic transformation in the body. Prodrugs are developed to improve bioavailability, reduce side effects, or enable targeted delivery. Metabolites are the compounds formed when the body breaks down a drug. Both prodrugs and metabolites appear in the Section 3(d) Explanation as derivatives of known substances.
Tenofovir disoproxil fumarate (TDF), the prodrug of tenofovir used in HIV and hepatitis B treatment, illustrates the issue. Tenofovir itself is a nucleotide analogue antiviral. TDF is the orally bioavailable prodrug. In India, generic manufacturers challenged Gilead’s TDF-related patents on Section 3(d) grounds, arguing that TDF is a known derivative of tenofovir and that Gilead had not demonstrated enhanced therapeutic efficacy of TDF over tenofovir (administered parenterally). Gilead’s India patent strategy for tenofovir alafenamide (TAF), the successor prodrug, incorporated lessons from the TDF experience, including negotiating voluntary licenses through the Medicines Patent Pool as an alternative to contested prosecution.
Drug Delivery System Patents
Novel drug delivery systems, including nanoparticle formulations, liposomal encapsulation, microsphere technologies, and implantable devices, present a more nuanced Section 3(d) profile. These inventions often involve delivery of known APIs in forms that change the drug’s pharmacokinetic profile substantially. When the delivery system change produces a clinically documented improvement, such as Abraxane (nab-paclitaxel) achieving superior tumor delivery and reduced hypersensitivity reactions compared to Cremophor-based paclitaxel, the therapeutic efficacy argument is substantively stronger than it is for pure polymorph or salt form patents. The evidentiary record from clinical trials supports the claim directly.
The challenge is that delivery system patents frequently claim the platform technology generically rather than the specific demonstrated therapeutic advantage. An IPO examiner applying Section 3(d) will ask: does this specific formulation of this specific drug show enhanced therapeutic efficacy over the existing approved formulation? A broad platform claim that does not answer that drug-specific question is vulnerable.
Key Takeaways: The Evergreening Roadmap
The India-specific Section 3(d) filter creates a two-tier IP environment. Primary NCE patents covering genuinely new chemical entities are generally insulated from Section 3(d) attack, though empirical data shows the IPO raises the objection even against NCE applications at a non-trivial rate. Secondary patents covering polymorphs, salts, metabolites, and prodrugs face near-certain 3(d) challenge with a low grant probability unless the applicant has published comparative therapeutic data from clinical trials or robust pharmacodynamic studies. The commercially rational response for innovator companies is to build the evidentiary record for India-specific therapeutic comparisons into Phase II and Phase III protocol design, rather than treating it as a prosecution afterthought.
8. Comparative Jurisdiction Analysis: US, EPO, and India Side by Side
United States: Non-Obviousness Under 35 U.S.C. Section 103
The US standard for patentability of incremental pharmaceutical inventions is non-obviousness under 35 U.S.C. Section 103, interpreted through the four-part Graham v. John Deere Co. factual framework: scope and content of prior art, differences between the prior art and the claimed invention, level of ordinary skill in the art, and secondary considerations including commercial success, long-felt need, and failure of others.
For a polymorph or new salt form, the US examiner asks: would a person of ordinary skill in the art have been motivated to prepare this specific crystal form or salt, and would they have had a reasonable expectation of success? The USPTO’s obviousness analysis for polymorphs has been contested terrain following Pfizer Inc. v. Apotex Inc. (Fed. Cir. 2007), where the Federal Circuit held that a pharmaceutical salt of an approved drug could be obvious if the prior art provided sufficient motivation and expectation of success for its preparation. But the court also noted that unexpected results, even results short of therapeutic superiority, can overcome an obviousness rejection.
The key difference from India: in the US, unexpected physical properties, including unusual solubility, stability, or bioavailability, are cognizable evidence of non-obviousness even without any link to superior clinical outcomes. A US secondary patent applicant can prevail by showing that their polymorph’s properties were unpredictable, without showing that the unpredictability matters therapeutically.
European Patent Office: Inventive Step and the Problem-Solution Approach
The EPO evaluates inventive step under Article 56 of the European Patent Convention using the problem-solution approach. The method requires identifying the closest prior art, determining the objective technical problem the invention solves over that prior art, and asking whether a person skilled in the art would have arrived at the claimed solution in an obvious way.
For pharmaceutical secondary patents, the EPO approach focuses on whether the technical effect achieved by the claimed compound, whether improved stability, bioavailability, or processing characteristics, would have been predictable from the prior art or would have required inventive skill to achieve. Technical advantages in the EPO’s analysis do not need to be therapeutic advantages. A polymorph with unexpectedly superior storage stability solves the objective technical problem of ‘how to improve shelf life and manufacturing reliability’ in a way that a skilled person could not have obviously arrived at from the prior art. That is sufficient for inventive step at the EPO.
The EPO’s framework does not ask what the technical advantage means for patients. It asks whether the technical advantage was obvious. This is a fundamentally different inquiry from India’s Section 3(d).
The Three-Jurisdiction Comparison Table
Feature
India (Section 3(d))
United States (35 U.S.C. Section 103)
European Patent Office (Art. 56 EPC)
Core inquiry
Enhanced therapeutic efficacy over known substance
Non-obviousness to person of ordinary skill
Inventive step via problem-solution approach
Nature of test
Substantive eligibility filter for specific compound classes
Universal inventiveness standard
Universal inventiveness standard
Secondary patent baseline
Known substance (directly preceding compound in chemical family)
Closest prior art, typically the approved compound
Closest prior art
Physical property advantages
Insufficient unless linked to clinical outcome
Cognizable as unexpected results evidence
Cognizable as objective technical effect
Bioavailability data
Insufficient without clinical outcome linkage
Sufficient unexpected result in many contexts
Sufficient technical effect if unexpected
Clinical data requirement
Required for pharmaceutical therapeutic efficacy
Not required; unexpected physicochemical results accepted
Not required; unexpected technical effects accepted
Burden allocation
Presumption that derivatives are same substance; applicant bears burden to rebut
Examiner must establish prima facie obviousness; applicant then responds
Examiner uses problem-solution structure; inventiveness must affirmatively appear
Average pharma secondary patent grant rate
Low for contested applications (estimated under 20% with pre-grant opposition)
Moderate to high depending on prosecution
Moderate to high depending on application quality
Implications for Global IP Strategy
A company designing global patent strategy for a secondary pharmaceutical asset should treat the India prosecution as a structurally separate track requiring different evidence than US or European prosecution. US and European prosecution can proceed on physicochemical unexpected results alone. India prosecution requires a therapeutic efficacy narrative supported by comparative clinical or pharmacodynamic data. The prosecution timelines are also different: India’s four-to-five-year average pendency means the India grant decision often comes after the drug has been marketed for years, and the post-filing evidence that becomes available during commercial Phase IV can be strategically submitted into Indian prosecution.
Key Takeaways: Comparative Framework
India is the only major pharmaceutical market where incremental innovations must clear a therapeutic superiority threshold before reaching the traditional novelty and inventive step analysis. The US and EPO systems allow non-therapeutic technical advantages to establish patentability for incremental pharmaceutical inventions. India’s Section 3(d) is not a stricter version of those tests; it is an additional, upstream filter operating on a different evidentiary dimension entirely.
9. Strategic Prosecution Playbook for Innovator Companies
The R&D-IP Integration Imperative
Conventional pharmaceutical R&D-to-patent pipelines treat patent strategy as a downstream activity: the chemistry team optimizes a compound and hands it to legal, which files the application. This model works adequately in US and European prosecution. It fails in India. A Section 3(d)-proof India prosecution strategy requires IP and clinical design teams to work in parallel from the compound optimization stage.
The specific integration points are: at the salt selection and polymorph screening stage, design the comparative assay protocol to include therapeutic comparators rather than only physicochemical comparators. At Phase I protocol design, include an arm or cohort specifically comparing the optimized form to the baseline compound’s clinical pharmacology, even if the regulatory submission does not require such a comparison. At Phase II, power at least one secondary endpoint to detect a meaningful difference in therapeutic outcome between the new form and the prior compound, not merely between the drug and placebo.
This design discipline generates the comparative therapeutic data that Section 3(d) requires without creating separate India-specific clinical programs, which would be prohibitively expensive. The data generated for regulatory and clinical purposes can serve dual duty in patent prosecution if the protocol is designed with that in mind.
Claim Architecture for India
Claim drafting for India should prioritize claims that are most defensible under Section 3(d), which means emphasizing the therapeutic functional result rather than structural characteristics alone. A claim that recites ‘a method of treating CML comprising administering a therapeutically effective amount of compound X in polymorphic form beta’ is harder to attack under 3(d) than a product claim that recites only the crystal structure, because the method claim explicitly connects the form to the therapeutic use. Product claims covering the compound per se should be retained as lead claims but should be drafted in conjunction with method claims that make the therapeutic context explicit.
Combination claims covering the compound plus a specific formulation that achieves a demonstrable clinical advantage, such as a controlled-release matrix reducing peak plasma concentration and associated adverse effects, should be filed as independent claims rather than dependent claims, because they present the strongest Section 3(d) defense.
Managing Pre-Grant Opposition
Pre-grant opposition under Section 25(1) of the Indian Patents Act allows any person to oppose a published application before grant. The opposition can be filed on grounds including anticipation, obviousness, Section 3(d) non-patentability, and insufficient disclosure. Generic manufacturers, particularly Cipla, Natco Pharma, Aurobindo, and Sun Pharma’s domestic generic divisions, maintain dedicated pre-grant opposition teams that monitor application publications through the Indian Patent Office journal.
An innovator company should anticipate a pre-grant opposition for any secondary pharmaceutical patent within 18-24 months of application publication. The prosecution strategy should be designed from filing to be opposition-ready: the specification should proactively disclose the best available comparative efficacy data, the claims should be narrowly drafted to the specific form and therapeutic advantage, and the prosecution team should have a prepared response strategy that includes affidavit evidence from clinical experts on the therapeutic efficacy question.
Post-Filing Evidence Submission Strategy
The Calcutta High Court’s ruling in Oyster Point Pharma confirms that post-filing evidence is admissible. The strategic use of post-filing evidence in Indian pharmaceutical prosecution follows a specific logic: file the application early to secure priority, then build the evidentiary record during prosecution through affidavits submitted under Section 79, expert declarations, and clinical trial data submitted as prosecution history.
Post-filing evidence cannot introduce new claims or expand the scope of the disclosed invention. But it can support claims already in the specification by providing comparative therapeutic data that was not available at the filing date. Companies with large India pharmaceutical portfolios should build an internal India evidence calendar that tracks prosecution timelines, identifies the window for post-filing evidence submission relative to any pending opposition proceedings, and ensures clinical teams are briefed on the evidentiary needs of active prosecution files.
Key Takeaways: Innovator Prosecution Strategy
India-specific prosecution success requires clinical trial design that generates therapeutic comparator data, claim architecture that makes the therapeutic benefit explicit, opposition-ready documentation from the filing date forward, and a post-filing evidence program tied to the prosecution calendar. Companies that treat India prosecution as a copy-and-translate exercise from US or European prosecution will consistently lose to pre-grant opponents who understand Section 3(d) better than they do.
10. Generic Company Playbook: Using Section 3(d) as a Commercial Weapon
Pre-Grant Opposition as a Business Development Function
For Indian generic companies, Section 3(d) is not an obstacle. It is a strategic asset. A successful pre-grant opposition that defeats a secondary patent eliminates an exclusivity barrier that might otherwise delay generic launch by two to eight years. At generic market scale, even one or two years of accelerated market entry on a high-volume product can represent hundreds of millions of rupees in revenue.
Cipla’s pre-grant opposition against Roche’s erlotinib (Tarceva) polymorph patent is the canonical example of this strategy executed at commercial scale. Cipla challenged the polymorph patent on Section 3(d) grounds and won, enabling its generic erlotinib to reach the market far earlier than Roche’s secondary patent would otherwise have permitted. Natco Pharma used a similar strategy against Bayer’s sorafenib, first through a compulsory license application and subsequently through patent challenges, including Section 3(d)-based arguments, to establish its generic Nexavar. These cases were not isolated legal victories; they were coordinated commercial operations supported by dedicated scientific and legal teams.
Building a 3(d) Opposition Program
A systematic generic opposition program targets secondary patents that meet three criteria: the originator drug is high-volume or high-value in the Indian market, the secondary patent lacks published comparative therapeutic efficacy data, and the patent term on the secondary filing extends meaningfully beyond the primary composition-of-matter patent’s expiry.
The scientific work required to execute a successful Section 3(d) opposition involves reviewing the existing therapeutic literature to establish that the approved compound (the known substance baseline) already achieves the clinical outcomes claimed for the new form, identifying pharmacological publications or meta-analyses confirming therapeutic equivalence between different forms or formulations of the drug, and retaining expert witnesses who can provide affidavit testimony that the claimed therapeutic advantage of the new form is not established by the available clinical literature.
This scientific work is tractable for drugs with well-developed clinical literatures, which describes most commercially significant pharmaceutical products facing secondary patent filings. The generic company need not prove that the new form is therapeutically inferior; it only needs to establish that the applicant has not demonstrated therapeutic superiority, which is a negative burden far easier to discharge than the positive burden the applicant bears.
Post-Grant Revocation as a Fallback
When a pre-grant opposition fails or is not filed in time, post-grant revocation under Section 64 remains available. Section 64 allows any interested person, including a generic manufacturer who faces infringement exposure, to petition the High Court for revocation on the same grounds available in pre-grant opposition. Section 3(d) is explicitly listed as a revocation ground. The revocation path is more expensive and slower than pre-grant opposition, but it provides a fallback when a secondary patent has been granted and is being enforced against a generic product.
Several high-profile revocation proceedings have successfully invalidated secondary pharmaceutical patents in India on Section 3(d) grounds, confirming that the provision operates as a validity check throughout the patent’s life, not only at the pre-grant stage.
Freedom-to-Operate Analysis in a Section 3(d) Environment
Generic companies conducting freedom-to-operate (FTO) analysis for Indian launches must treat secondary patents differently than primary patents. A secondary patent, particularly one covering a polymorph, salt, or formulation without a published comparative therapeutic efficacy record, warrants a lower FTO concern than an equivalent secondary patent in the US or Europe. The Section 3(d) vulnerability of that patent means its enforceability is substantially discounted, and any infringement action would face an immediate invalidity counterclaim on Section 3(d) grounds.
This analysis changes the commercial risk calculus for generic launches in India in ways that are not reflected in standard global FTO models. Indian FTO assessments should include a Section 3(d) validity scoring component for every secondary patent identified in the freedom-to-operate search.
Key Takeaways: Generic Company Playbook
Pre-grant opposition is a business development activity, not merely a legal function. The scientific work to support a Section 3(d) opposition relies on published therapeutic literature, not original research, making it cost-effective relative to the commercial value of a successful challenge. Post-grant revocation provides a fallback for patents that grant despite lacking adequate therapeutic efficacy evidence. FTO models for Indian launches should explicitly discount secondary patents’ blocking effect based on their Section 3(d) exposure.
11. Biologics, Biosimilars, and the Next Frontier of the 3(d) Test
Why Biologics Present a Different Section 3(d) Challenge
The analytical framework developed in Novartis was built around small-molecule chemistry: a defined compound with a precise crystal structure and measurable pharmacokinetic properties. Biologics, including monoclonal antibodies, fusion proteins, enzyme replacement therapies, and nucleic acid therapeutics, do not fit this model cleanly. A biologic drug’s identity is defined by its primary amino acid sequence, three-dimensional folding, glycosylation pattern, and higher-order structure. Two batches of the same biologic from the same manufacturer are not identical at the molecular level in the way two polymorphs of imatinib mesylate are either the alpha or the beta form.
The question of how Section 3(d) applies to biologics is not fully resolved by existing case law. The Novozymes decision extended the provision to biochemical enzymes and adopted a function-specific efficacy standard, which is encouraging for biologics analysis. But the complexity of biologic identity creates questions that enzyme patent cases do not fully address.
The Biosimilar Question
A biosimilar is a biologic that the regulatory authority has determined to be highly similar to an approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. The WHO, FDA, and EMA all maintain that approved biosimilars are interchangeable with their reference products for their approved indications.
If biosimilar interchangeability means the biosimilar is therapeutically equivalent to the reference product, then filing a patent in India on the biosimilar’s specific amino acid sequence variant or glycosylation profile as a ‘new form’ of the reference biologic faces a Section 3(d) problem by design. The applicant would need to show that the specific variant has enhanced therapeutic efficacy over the reference biologic, precisely the opposite of the regulatory showing required for biosimilar approval (which requires equivalence, not superiority).
For a ‘biobetter,’ which is a biologically derived product designed to be therapeutically superior to the reference biologic rather than merely similar, the Section 3(d) path is more tractable. A biobetter that demonstrably reduces immunogenicity, extends half-life enabling less frequent dosing, or improves tumor penetration through engineering changes has a therapeutic efficacy narrative that comparative clinical data can support. The challenge is that biobetter development is expensive, and the India market has historically not justified biobetter investment at the levels that might generate the comparative clinical data Section 3(d) requires.
Antibody-Drug Conjugates and Bispecific Antibodies
Next-generation antibody modalities including antibody-drug conjugates (ADCs) and bispecific antibodies present interesting Section 3(d) scenarios. An ADC is a monoclonal antibody conjugated to a cytotoxic payload. The antibody component may be a known biologic (e.g., trastuzumab, a known HER2-targeting antibody). The conjugation to a new linker-payload system creates a new chemical entity in the combined molecular sense, but the antibody component is known. An Indian patent examiner could potentially argue that the ADC is a derivative of a known substance (the unconjugated antibody) and invoke Section 3(d).
In practice, a well-constructed ADC patent would distinguish the ADC from the known antibody on the basis that the cytotoxic payload component creates a genuinely new chemical entity, not a derivative. The better Section 3(d) defense is to argue that the ADC is not a ‘new form’ of the antibody but an entirely different molecular entity with distinct pharmacological properties. Whether Indian courts would accept that characterization for a linker-payload variant of an approved antibody has not been definitively litigated.
Gene Therapies and Cell Therapies
Gene and cell therapies, including viral vector-mediated gene delivery and CAR-T cell therapies, are the next generation of medicines for which Section 3(d) analysis is almost entirely uncharted. A viral vector, such as an adeno-associated virus (AAV) capsid variant, is a biological molecule. If the wild-type AAV capsid is a ‘known substance,’ is an engineered capsid variant with improved liver tropism a ‘new form of a known substance’? If so, must the applicant show enhanced therapeutic efficacy of gene delivery compared to the wild-type capsid?
The logic of the Novozymes function-specific approach would likely apply. The function of an AAV capsid is efficient gene delivery to target tissue. Improved transduction efficiency, reduced immunogenicity, or broader tissue tropism could each constitute functional enhancements relevant to efficacy in the context-specific sense. But the IPO has not issued examination guidelines for these modalities, and no published case law addresses them. Companies developing gene therapies with India portfolio strategies should begin engaging the IPO on examination practice for novel capsid variants and gene therapy constructs before filings mature, both to shape examination practice and to identify the evidentiary record needed.
AI-Driven Drug Discovery and Section 3(d)
Computational drug discovery platforms, including generative chemistry systems from companies like Schrödinger, Insilico Medicine, and Recursion Pharmaceuticals, are increasingly producing compounds that are structurally similar to known drugs but optimized for specific molecular properties. These computationally designed variants are often structurally analogous to known compounds, differing by a small number of atomic substitutions that confer predicted improvements in binding affinity, selectivity, or metabolic stability.
Such computationally designed analogs face a particularly acute Section 3(d) risk in India. They are, almost by definition, new forms of structurally known substances. Their design rationale is typically physicochemical optimization, which falls squarely into the category of advantages that Novartis held insufficient. And the evidence that AI predictions are clinically valid is often limited to in silico predictions or early in vitro data at the time of patent filing, precisely the type of evidence that the Novartis standard requires to be supplemented with comparative therapeutic data.
For AI-first drug discovery companies seeking Indian patents on computationally designed analog series, the prosecution strategy must include a committed plan to generate comparative pharmacodynamic and clinical data, with that plan documented in the patent specification and the prosecution history. A patent application that discloses only computational predictions and early in vitro data without a clear evidentiary roadmap toward therapeutic comparisons is likely to face an insurmountable 3(d) objection.
Key Takeaways: Biologics and Emerging Modalities
Section 3(d)’s application to biologics, gene therapies, and AI-designed drug analogs is judicially unsettled but directionally clear from Novozymes: efficacy is function-specific, and functional enhancement relevant to the molecule’s intended clinical role is the applicable standard. For biologics, the biosimilar interchangeability framework and the biobetter clinical data program are the principal levers for managing 3(d) exposure. For emerging modalities, the lack of IPO examination guidelines creates both risk and an opportunity to shape practice through early engagement.
The Discount Framework for India Market Exclusivity
Institutional investors pricing Indian pharmaceutical market exclusivity must apply a specific Section 3(d) discount to the NPV contribution of any secondary patent. The discount is not binary. It is a probability-weighted adjustment based on four factors: whether the patent claims a compound type explicitly listed in the Section 3(d) Explanation (salts, polymorphs, esters, metabolites, isomers, combinations), whether published comparative therapeutic efficacy data exists for the claimed form versus the baseline compound, whether the asset is commercially significant enough to attract a pre-grant opposition from domestic generics, and whether the originator has a documented track record of successful Section 3(d) defense in the IPO or Indian courts.
An asset scoring high on all four risk factors, a polymorph of a high-volume oncology drug with no published comparative clinical data and a history of Cipla or Natco pre-grant oppositions, should have its India secondary patent contribution to NPV discounted by 70-90%. An asset with published Phase III comparative data demonstrating superior therapeutic outcomes, no pending opposition proceedings, and claims drafted explicitly around the therapeutic benefit, should carry a lower discount, perhaps 20-40%, reflecting residual litigation risk.
Portfolio-Level Exposure for Major India Pharmaceutical Stakeholders
Sun Pharma’s branded generic segment and its US specialty pharma portfolio both have India exclusivity components tied to secondary patents on several commercial products. Analysts should evaluate each secondary patent in Sun’s India portfolio against the Section 3(d) discount framework, particularly for products where the primary patent has already expired and the revenue stream is sustained entirely by secondary patent protection.
Cipla’s business model inverts the analysis: Cipla is a primary beneficiary of Section 3(d) through its opposition program. Pre-grant opposition successes accelerate Cipla’s domestic generic launches and contribute directly to revenue. Analysts should monitor Cipla’s pre-grant opposition filings as a leading indicator of the company’s pipeline of imminent generic launches in India.
Aurobindo Pharma and Lupin, both with substantial US Paragraph IV challenge programs, deploy complementary India-market Section 3(d) expertise. The legal teams that execute Paragraph IV challenges in the US operate with different tools but overlapping strategic logic with the India pre-grant opposition function, and companies that invest in India IP challenge capability tend to build transferable expertise that strengthens their US generic challenge programs.
For multinational originators including Pfizer, AstraZeneca, Novartis, Roche, and Johnson and Johnson, the India secondary patent portfolio should be separately modeled from the global patent portfolio. The standard global IP contribution-to-valuation models applied in sell-side coverage of these companies systematically overstate India market exclusivity value for secondary patents, because they apply global grant probability assumptions to a jurisdiction with a structurally different and far more challenging patentability standard.
The Compulsory License Wild Card
Section 3(d) is one mechanism limiting pharmaceutical patent scope in India. Compulsory licensing under Section 84 is a separate, parallel mechanism that can override even valid primary patents if the drug is not available at a reasonably affordable price, is not meeting the public health requirements of India, or is not manufactured to a sufficient extent in India. The government exercised this provision in 2012 for Bayer’s sorafenib, granting Natco a compulsory license at a royalty rate of 6% of net sales.
For investors, compulsory licensing and Section 3(d) operate on different parts of the exclusivity value chain. Section 3(d) attacks the secondary patent before or at grant. Compulsory licensing attacks a valid primary patent at the commercial stage if access conditions are not met. A complete India-market risk analysis for a pharmaceutical asset must model both risks independently and consider their combined effect on the probability of sustained exclusivity at innovator pricing.
India’s Generic Export Value as a Mirror Risk
India supplies approximately 40% of US generic drug consumption by volume and is the leading supplier of generic pharmaceuticals to many low-and-middle-income countries. The strength of India’s generic industry, which Section 3(d) directly supports, is also an important valuation input for US-listed companies dependent on Indian API or finished dose supply. Supply chain disruptions, regulatory import alerts, or currency fluctuations affecting Indian generics have global price consequences for markets dependent on Indian supply.
Conversely, analysts pricing Indian generic companies for US or European investors must account for the strategic value of the domestic Section 3(d) legal capability as a component of those companies’ competitive moats. An Indian generic company with a demonstrated track record of successful Section 3(d) pre-grant oppositions has a defensible competitive advantage in the Indian market that is not fully reflected in traditional generic company valuation models.
Key Takeaways: Investment Strategy
Apply a probability-weighted Section 3(d) discount of 70-90% to India secondary patent NPV for polymorph and standard salt form patents without published comparative therapeutic efficacy data. Apply a lower discount of 20-40% for formulation and route-of-administration patents with supporting clinical comparator data. Model compulsory license risk separately. Treat Indian generic companies’ Section 3(d) opposition capabilities as a distinct competitive asset in valuation. Multinationals’ India market exclusivity is systematically overstated in global IP models that apply US grant probability assumptions to secondary pharmaceutical patents.
13. Frequently Asked Questions
Is Section 3(d) TRIPS-compliant?
Yes, under all authoritative interpretations. The Madras High Court upheld the provision’s constitutional validity in the Novartis writ petition proceedings. India’s position, sustained in WTO Trade Policy Reviews and bilateral negotiations, is that TRIPS Article 27 requires patent protection for inventions that are new, involve an inventive step, and are capable of industrial application, but does not define ‘invention.’ India has used that definitional gap to exclude certain subject matter, specifically new forms of known substances without enhanced efficacy, from the category of ‘inventions’ under domestic law. The Doha Declaration on TRIPS and Public Health explicitly affirmed member states’ rights to use TRIPS flexibilities to protect public health, including through interpretation of patentability criteria. Multiple WTO dispute settlement proceedings have not produced a ruling that Section 3(d) violates TRIPS, and no formal WTO dispute has been filed specifically targeting the provision.
What evidentiary standard does the IPO apply to ‘enhanced efficacy’ data?
The IPO does not apply a defined quantitative threshold. The standard from Novartis is that the therapeutic efficacy enhancement must be ‘significant.’ The court did not define significant as a percentage improvement or a clinical threshold. Practice at the IPO and in court decisions suggests that the evidence must be comparative, direct (comparing the new form to the known substance rather than to placebo or to a different drug), and interpretable as showing a therapeutic benefit to patients. Affidavit evidence from qualified clinicians or pharmacologists is the standard submission format. Peer-reviewed published clinical trial data comparing the new form to the baseline compound is the most persuasive form of evidence, though unpublished but methodologically sound comparative studies submitted during prosecution are also accepted.
Can an improved safety profile satisfy Section 3(d)?
The Novartis court left the door open for safety improvements to constitute enhanced therapeutic efficacy. The Court’s reasoning, which held that efficacy in a pharmaceutical context relates to the drug’s function in treating or managing disease, is broad enough to encompass significant reductions in adverse effects as therapeutic improvements. A compound that achieves equivalent anti-tumor activity with a 50% reduction in dose-limiting toxicity is therapeutically superior in a clinically meaningful sense. The evidentiary bar is the same: the applicant must provide comparative data from clinical or pharmacological studies demonstrating the safety improvement. Marketing-based claims of improved tolerability without comparative data are insufficient.
How do Indian CDMOs use Section 3(d) intelligence in partnership negotiations?
Indian contract development and manufacturing organizations, including Divi’s Laboratories, Syngene International, Laurus Labs, and Piramal Pharma Solutions, use IP intelligence platforms to conduct freedom-to-operate analysis for their clients’ molecules before undertaking development or manufacturing mandates. In a Section 3(d) context, FTO analysis for India-market manufacturing involves identifying all secondary patents covering the API and evaluating their Section 3(d) vulnerability. A CDMO that can quantify and communicate the Section 3(d) challenge risk on a client’s patent portfolio brings a legally sophisticated, commercially valuable perspective to the partnership. This capability, which requires integrating patent prosecution data with clinical literature analysis, is increasingly a differentiator for CDMOs competing for complex, high-value client relationships.
How do Section 3(d) and data exclusivity interact?
Data exclusivity under India’s Drugs and Cosmetics Act protects undisclosed clinical trial data submitted for regulatory approval from unfair commercial use for a limited period, but India has not implemented a fully TRIPS-plus data exclusivity regime. The interaction between data exclusivity and Section 3(d) is limited in practice: data exclusivity protects the regulatory data package, while Section 3(d) addresses patentability. A drug without an Indian patent due to Section 3(d) rejection can still benefit from any available data exclusivity period, though generic manufacturers can file their own independent data with the regulator to avoid relying on the originator’s undisclosed data. For secondary pharmaceutical inventions, data exclusivity is rarely the primary commercial protection mechanism. Section 3(d) shapes the patent protection question. Data exclusivity operates as a separate, narrower safeguard for the regulatory approval pathway.
What is the USTR’s current position on Section 3(d)?
The Office of the United States Trade Representative has maintained India on its Priority Watch List in multiple annual Special 301 Reports, citing Section 3(d)’s restrictions on patent-eligible subject matter as a significant IP concern. PhRMA’s 2025 Special 301 submission reiterated these concerns. The US government position is that Section 3(d) creates major obstacles for US pharmaceutical innovators and departs from international IP norms. India’s position is that the provision is TRIPS-compliant, domestically developed through democratic legislative processes, and essential to public health goals. No bilateral free trade agreement between the US and India is in force that would require modification of Section 3(d), and the provision’s deep political support in India across party lines makes legislative amendment politically unlikely regardless of trade negotiation outcomes.
This pillar page draws on public court records, IPO examination data from academic analyses including Sampat and Shadlen (PLOS ONE, 2018), WIPO statistics, PhRMA and USTR public submissions, and publicly available prosecution histories. It does not constitute legal advice. IP teams and institutional investors should engage qualified Indian patent counsel for specific asset analysis.
